

Eloxx Pharmaceuticals, Inc.  
Form 8-K  
August 03, 2018

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): July 30, 2018**

**Eloxx Pharmaceuticals, Inc.**

**(Exact name of registrant as specified in its charter)**

**Delaware**

**001-31326**

**84-1368850**

(State or other jurisdiction (Commission (IRS Employer  
of incorporation) File Number) Identification No.)

950 Winter Street

02451

Waltham, MA

(Address of principal executive offices) (Zip Code)

Registrant's telephone number, including area code: (781) 577-5300

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligations of the registrant under any of the following provisions:

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On July 30, 2018, Eloxx Pharmaceuticals, Inc. (the “Company”) was advised by Dr. Pedro Huertas of his intention to resign as the Company’s Chief Medical Officer. The duties of the Chief Medical Officer will be overseen by the Company’s Chief Operating Officer on an interim basis.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**ELOXX  
PHARMACEUTICALS,  
INC.**

Date: August 3, 2018 By: /s/ Gregory Weaver  
Gregory Weaver  
Chief Financial  
Officer